newsfilter
← Earnings
Earnings Releases·

IMUNON — Third Quarter 2026 Earnings Summary

IMUNON, Inc. reported a net loss of $3.8 million for the third quarter of 2026, with operating expenses totaling $3.4 million. The company advanced its lead candidate IMNN-001 in a Phase 3 trial for advanced ovarian cancer, supported by a new Cooperative Research and Development Agreement with the National Cancer Institute. Recent corporate developments include a debt-for-equity exchange reducing debt by approximately 43% and an agreement to sell rights to ThermoDox to VoxelDox Therapeutics. As of September 30, 2026, the company held $4.0 million in cash and cash equivalents alongside $5.0 million in restricted cash.

Company
IMUNON INC
Sector
Healthcare
Industry
Biotechnology